Brookline Capital Management Analysts Increase Earnings Estimates for Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Stock analysts at Brookline Capital Management boosted their FY2025 earnings per share estimates for shares of Lantheus in a research note issued to investors on Wednesday, July 17th. Brookline Capital Management analyst K. Dolliver now expects that the medical equipment provider will post earnings per share of $7.69 for the year, up from their prior forecast of $7.20. The consensus estimate for Lantheus’ current full-year earnings is $6.46 per share.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. The company had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%.

A number of other research firms have also issued reports on LNTH. B. Riley increased their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. JMP Securities increased their target price on Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th. Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Finally, SVB Leerink raised their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $113.86.

Lantheus Price Performance

LNTH stock opened at $116.79 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a market cap of $8.09 billion, a P/E ratio of 17.83 and a beta of 0.51. The stock has a 50-day simple moving average of $86.32 and a 200-day simple moving average of $69.83.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. UMB Bank n.a. boosted its position in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 247 shares during the period. GAMMA Investing LLC boosted its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the period. Principal Securities Inc. acquired a new position in Lantheus during the 4th quarter worth $28,000. Fidelis Capital Partners LLC acquired a new position in Lantheus during the 1st quarter worth $34,000. Finally, FinTrust Capital Advisors LLC boosted its position in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 232 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insiders Place Their Bets

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now owns 11,978 shares of the company’s stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Insiders have sold a total of 44,799 shares of company stock valued at $3,769,262 in the last quarter. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.